B2Gold and Vertex Pharmaceuticals stand out as strong buys, driven by robust fundamentals, sector leadership, and clear ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

The Waltham biotech signs more pharma deals than the average company, and already lists Vertex, Takeda and Biogen as its ...

Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing ...

Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

And one of the best ways to cash in on that is to invest in stocks that can exceed the market's performance. Two that look ...

It's the second time this year the stock has slumped significantly in one day, and it might represent another attractive ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts ...

New research on eltrombopag plus immunosuppressive therapy for severe aplastic anemia in young patients challenges the ...

In Phase III studies, Tonmya showed significantly superior analgesic effects in patients with fibromyalgia versus placebo.

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...